诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVO 诺和诺德

交易中 12-18 09:33:44 EST

48.29

+0.52

+1.09%

最高48.31	最低47.96	成交量64.81万
今开48.00	昨收47.77	日振幅0.73%
总市值2,144亿	流通市值1,539亿	总股本44.39亿
成交额3,122万	换手率0.02%	流通股本31.88亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVO","market":"US","secType":"STK","nameCN":"诺和诺德","latestPrice":48.2899,"timestamp":1766068424161,"preClose":47.77,"halted":0,"volume":648104,"delay":0,"floatShares":3187922885,"shares":4439052849,"eps":3.665526,"marketStatus":"交易中","change":0.5199,"latestTime":"12-18 09:33:44 EST","open":48,"high":48.31,"low":47.96,"amount":31220004.437951997,"amplitude":0.007327,"askPrice":48.29,"askSize":300,"bidPrice":48.27,"bidSize":491,"shortable":3,"etf":0,"ttmEps":3.665526,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1766091600000},"marketStatusCode":2,"adr":1,"adrRate":1,"listingDate":363499200000,"exchange":"NYSE","adjPreClose":47.77,"dividendRate":0.034952,"preHourTrading":{"tag":"盘前","latestPrice":48.02,"preClose":47.77,"latestTime":"09:29 EST","volume":168928,"amount":8106295.568320001,"timestamp":1766068199568},"postHourTrading":{"tag":"盘后","latestPrice":47.6384,"preClose":47.77,"latestTime":"19:59 EST","volume":576273,"amount":27513366.0548,"timestamp":1766019584083},"volumeRatio":4.949246,"impliedVol":0.445,"impliedVolPercentile":0.236},"requestUrl":"/m/hq/s/NVO/tweets","defaultTab":"tweets","newsList":[{"id":"2592901594","title":"礼来重磅口服减肥药试验取得新进展：针剂转口服后有效维持减重成果，已向FDA递交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2592901594","media":"华尔街见闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592901594?lang=zh_cn&edition=full","pubTime":"2025-12-18 22:10","pubTimestamp":1766067036,"startTime":"0","endTime":"0","summary":"礼来在研口服GLP-1减肥药orforglipron后期试验证实，患者可在礼来的Zepbound或诺和诺德的Wegovy注射剂切换至orforglipron口服药后，有效维持减重，缓解停针反弹这一核心痛点。公司已向FDA提交上市申请并获优先审评。凭借“无针化”优势，礼来有望在口服减重药赛道中抢占诺和诺德的存量市场。","market":"nz","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3761656","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3761656","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LLY","NVO"],"gpt_icon":1},{"id":"2592819921","title":"诺和诺德收到警告信","url":"https://stock-news.laohu8.com/highlight/detail?id=2592819921","media":"药智网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592819921?lang=zh_cn&edition=full","pubTime":"2025-12-18 11:57","pubTimestamp":1766030268,"startTime":"0","endTime":"0","summary":"近日，诺和诺德收到FDA对其Catalent工厂的警告信，包括毛发污染等严重违规问题。更令人担忧的是，诺和诺德未能对偏差进行充分调查，常在缺乏数据支持的情况下仓促确定根本原因。2025年9月，FDA明确要求诺和诺德对不合规药品实施召回，后者承诺启动召回程序。日前，诺和诺德发言人表示“已收到警告信，正积极与FDA合作解决问题”，但未就合作伙伴的困境作出详细回应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218120156a6b0b7f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251218120156a6b0b7f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BKVL7J92.USD","LU1093756168.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","BK4532","LU0154236417.USD","BK4007","BK4599","BK4585","NVO","BK4588"],"gpt_icon":1},{"id":"2592963340","title":"全球高质量企业1000强出炉，英伟达夺冠 台积电居前十","url":"https://stock-news.laohu8.com/highlight/detail?id=2592963340","media":"财闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592963340?lang=zh_cn&edition=full","pubTime":"2025-12-17 12:09","pubTimestamp":1765944592,"startTime":"0","endTime":"0","summary":"据胡润百富12月16日消息，胡润研究院在深圳福田发布《2025胡润全球高质量企业TOP1000》。美国继续在胡润全球1000强中以410家公司领先，但减少了3家，中国增加了24家公司，以158家公司位居第二，其中，国有企业83家，非国有企业75家。美国和中国占胡润全球1000强的55%。胡润集团董事长兼首席调研官胡润表示，胡润全球1000强是投资者认为在未来10年左右有可能创造最多利润的公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217121641a6ac3e7a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217121641a6ac3e7a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2413666699.HKD","LU0276348264.USD","TSLA","NVDA","LU0210533765.USD","LU0345770993.USD","LU0964807845.USD","LU2357305700.SGD","BABA","AMZN","SNVD.UK","NVDY","IE00BFSS8Q28.SGD","LU1323610961.USD","LU1804176565.USD","IE00B3SWFQ91.USD","LU2249611893.SGD","2NVD.UK","MSFT","LU2125909593.SGD","NVDU","LU2023250330.USD","IE00BD6J9T35.USD","LU0056508442.USD","LU2065171402.SGD","BK4543","LU0792757196.USD","LU2360107168.USD","NVD","GOOGL","NVO","NVD2.UK","BK4526","NVD3.UK","LU0345768153.USD","LU0820562030.AUD","NVDS","03145","IE00B1XK9C88.USD","LU0528227936.USD","LU0061475181.USD","IE00B5TLWC47.USD","NVDD","BK4529","IE00BKPKM429.USD","LU1992135399.USD","NVIW.SI","LU1023057109.AUD","LU0070217475.USD","NVDX","LU0557290698.USD","NVDS.UK","TSM","LU0942090050.USD","3NVD.UK"],"gpt_icon":1},{"id":"2592958156","title":"Wegovy®狂飙54%，诺和诺德为何仍裁9000人？","url":"https://stock-news.laohu8.com/highlight/detail?id=2592958156","media":"药事纵横","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592958156?lang=zh_cn&edition=full","pubTime":"2025-12-17 06:02","pubTimestamp":1765922574,"startTime":"0","endTime":"0","summary":"2025年第三季度，诺和诺德的核心产品Wegovy销售额同比狂飙54%，但公司随之而来的决定却让很多人吃了一惊：全球裁员9000人。截至12月10日收盘，诺和诺德股价报收于49.05美元，较前一日上涨5.8%，市值重回2170亿美元以上。守住Wegovy的当下市场份额，并全力押注于口服药和下一代多靶点药物的研发，以应对礼来等对手的迫近。2025年前九个月，美国贡献了超过六成收入，其中Wegovy推动肥胖护理板块CER增长达41%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217060537a6aaf72d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217060537a6aaf72d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVO","BK4585","IE00BKVL7J92.USD","BK4007","BK4532","BK4588","LU1093756325.SGD","LU1093756168.USD","BK4599","IE00BZ1G4Q59.USD","LU0154236417.USD"],"gpt_icon":1},{"id":"2591986534","title":"摩根大通：诺和诺德与白宫的定价协议将推动销量","url":"https://stock-news.laohu8.com/highlight/detail?id=2591986534","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591986534?lang=zh_cn&edition=full","pubTime":"2025-12-16 18:45","pubTimestamp":1765881927,"startTime":"0","endTime":"0","summary":"摩根大通 在与诺和诺德首席执行官Maziar Mike Doustdar交谈后称，诺和诺德的投资者需要考虑到，白宫的药品定价协议将对该集团的增长构成低个位数的百分比拖累。该行称，Doustdar表示，白宫关于美国联邦医疗 保险 定价的协议将促进销量增长，这应会在2026年年中开始显现，并足以抵消降价带来的影响。不过，降价与随后的销量增长之间可能会有滞后。该行补充说，多个市场的诺和泰 仿制药 也对集团增长构成潜在的不利因素。摩根大通称，尽管有迹象表明配方药（为替代已获批药物而定制的药物）的增长有所放缓，但Doustdar强调，一些使用配方药的患者可能仍然负担不起已获批的药品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216185750a6a948a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216185750a6a948a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2237443382.USD","LU2237443622.USD","LU0345770308.USD","LU1093756168.USD","LU2462157665.USD","LU0154236417.USD","NVO","LU0006306889.USD","LU1720051108.HKD","BK4599","LU2237443465.HKD","LU2237443895.HKD","LU2054465674.USD","IE00BLSP4452.SGD","LU0964807845.USD","IE00BJTD4V19.USD","BK4585","BK4504","BK4588","LU0211326755.USD","LU2023250843.SGD","LU2236285917.USD","LU2237443978.SGD","BK4007","LU1366192091.USD","LU0208291251.USD","IE00B3S45H60.SGD","IE00BZ1G4Q59.USD","LU2264538146.SGD","LU2417539215.USD","LU0265550946.USD","LU0820562030.AUD","LU0211326839.USD","LU1914381329.SGD","LU2023250330.USD","SG9999002224.SGD","LU0683600562.USD","LU0320765489.SGD","LU2430703178.SGD","LU1267930490.SGD","LU2552382215.SGD","LU0868494708.USD","LU2213496289.HKD","LU0640476718.USD","LU2756315664.SGD","LU1548497426.USD","LU0234572021.USD","IE00BJLML261.HKD","LU2211815571.USD"],"gpt_icon":0},{"id":"2590097795","title":"2025年药企全球裁员潮上10000人，辉瑞也宣布裁200多人！","url":"https://stock-news.laohu8.com/highlight/detail?id=2590097795","media":"药械VIP","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590097795?lang=zh_cn&edition=full","pubTime":"2025-12-12 19:34","pubTimestamp":1765539287,"startTime":"0","endTime":"0","summary":"2025年12月10日，辉瑞将在瑞士裁减200多个岗位，将当地员工数量从约300人缩减至约70人，此举是其多年成本削减计划及瑞士业务整体调整的一部分。报道称在拉尔接手后，其业务职责范围有所收窄。回溯今年，5月裁员143人，7月裁员87人，加上此次，仅在南旧金山的裁员总数已达348人。更令人震惊的是，自2024年4月以来，基因泰克已裁员800多人。诺德宣布：减肥药巨头诺和诺德宣布，将在全球范围内裁员约9000人。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212204350a69c06a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212204350a69c06a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1066051498.USD","LU0170899867.USD","LU0225284248.USD","SG9999002224.SGD","LU1057294990.SGD","LU1066053197.SGD","IE0002270589.USD","BK4588","BK4599","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4568","IE00BKVL7J92.USD","LU0321505439.SGD","IE00BLSP4239.USD","IE00BLSP4452.SGD","BK4532","LU1894683264.USD","BK4581","LU0234572021.USD","LU1093756325.SGD","SGXZ57979304.SGD","NVO","LU1093756168.USD","LU0289739699.SGD","IE00BBT3K403.USD","SG9999003800.SGD","BK4533","LU0058720904.USD","LU0225771236.USD","SG9999011175.SGD","PFE","BK4550","BK4534","IE00B19Z3581.USD","SG9999001176.SGD","LU1023059063.AUD","LU1883839398.USD","LU1894683348.USD","LU0456855351.SGD","SG9999002232.USD","LU0868494617.USD","SG9999013999.USD","IE000M9KFDE8.USD","SG9999001176.USD","LU0985481810.HKD","LU0306806265.USD","LU0306807586.USD","BK4592","IE00B19Z3B42.SGD"],"gpt_icon":0},{"id":"2590571782","title":"诺和诺德旗下药物司美格鲁肽在印度上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2590571782","media":"钛媒体快报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590571782?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:43","pubTimestamp":1765528995,"startTime":"0","endTime":"0","summary":"钛媒体App 12月12日消息，诺和诺德旗下药物司美格鲁肽在印度上市，定价落在每周24美元的低位区间。（广角观察）","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212165055a4446968&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212165055a4446968&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","LU1093756168.USD","NVO","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1093756325.SGD","BK4588","BK4585","LU0154236417.USD","BK4599","BK4007"],"gpt_icon":0},{"id":"2590557847","title":"诺和诺德在印度推出糖尿病治疗药物Ozempic。","url":"https://stock-news.laohu8.com/highlight/detail?id=2590557847","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590557847?lang=zh_cn&edition=full","pubTime":"2025-12-12 14:45","pubTimestamp":1765521953,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["NVO","LU0154236417.USD","BK4599","BK4532","IE00BZ1G4Q59.USD","LU1093756168.USD","BK4007","BK4588","BK4585","LU1093756325.SGD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2590515212","title":"诺和诺德(NVO)盘前升1.75% 分析师谨慎看待其价值回归","url":"https://stock-news.laohu8.com/highlight/detail?id=2590515212","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590515212?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:59","pubTimestamp":1765457968,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺和诺德(NVO)盘前股价延续升势，暂升1.75%，报49.91美元。诺和诺德今年股价暴跌，甚至退回到了2021年减肥药热潮爆发前的水平。尽管如此，分析师仍谨慎看好该公司股价恢复到合理水平。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/NDViNTE0MThlOGIzNGVjYjVmZmFmNTJlOTIxNzAyOTY1ODYyNw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDViNTE0MThlOGIzNGVjYjVmZmFmNTJlOTIxNzAyOTY1ODYyNw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"566163e37b9d8f8e565f1e9465bbe4ed","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"295294","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4532","IE00BZ1G4Q59.USD","BK4585","BK4599","LU1093756168.USD","LU1093756325.SGD","NVO","LU0154236417.USD","IE00BKVL7J92.USD","BK4007"],"gpt_icon":0},{"id":"1150141925","title":"诺和诺德股价短暂转负，因礼来称下一代药物在减重方面超越Zepbound，最终上涨1.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150141925","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150141925?lang=zh_cn&edition=full","pubTime":"2025-12-11 20:00","pubTimestamp":1765454446,"startTime":"0","endTime":"0","summary":"诺和诺德股价短暂转负，因礼来称下一代药物在减重方面超越Zepbound，最终上涨1.8%","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"883c6c6cb6346576187aa63a85c87473","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU2063271972.USD","LU0238689110.USD","LU0006306889.USD","LU2468319806.SGD","LU2237443382.USD","SG9999015978.USD","LU1035775433.USD","LU0640476718.USD","LU0823434740.USD","LU2237443549.SGD","LU2471134796.USD","LLY","LU2168564065.EUR","LU2361044865.SGD","LU2023250504.SGD","LU2471134879.HKD","LU1323610961.USD","BK4585","SG9999001176.USD","LU2108987350.USD","IE00BWXC8680.SGD","LU0096364046.USD","LU1983299246.USD","LU0203201768.USD","LU0417517546.SGD","IE00BKPKM429.USD","IE00BFTCPJ56.SGD","BK4007","LU0882574055.USD","LU2552382215.SGD","LU1623119135.USD","BK4516","IE00BK4W5M84.HKD","LU0323591593.USD","LU0943347566.SGD","LU0316494557.USD","SGXZ31699556.SGD","LU1291159041.SGD","LU2112291526.USD","LU0320765059.SGD","LU2357305700.SGD","SG9999015986.USD","SG9999015952.SGD","SG9999018857.SGD","LU0198837287.USD","SG9999017495.SGD","LU0672654240.SGD","LU1548497426.USD","LU2237443465.HKD","LU1366192091.USD","LU2361044949.HKD","LU2237443978.SGD","LU1551013342.USD","LU1814569148.SGD","LU2461242641.AUD","LU0320765992.SGD","LU2462157665.USD","GB00BDT5M118.USD","LU0354030438.USD","BK4588","BK4533","LU0203202063.USD","LU1023059063.AUD","IE00B775H168.HKD","LU2324357040.USD","IE0002141913.USD","BK4581","LU1917777945.USD","NVO","SGXZ57979304.SGD","SGXZ99366536.SGD","BK4599","LU0266013472.USD","LU0466842654.USD","LU2552382132.HKD","LU1868836591.USD","LU2089984988.USD","LU1989771016.USD","LU2237443622.USD","LU1712237335.SGD","LU1267930730.SGD","LU0786609619.USD","LU1127390331.HKD","LU0109391861.USD","IE0005OL40V9.USD","IE00B1XK9C88.USD","IE00BJJMRZ35.SGD","LU0882574139.USD","LU0353189763.USD","LU0061475181.USD","LU2168564149.EUR","IE00B1BXHZ80.USD","LU1280957306.USD","LU2236285917.USD","BK4534","LU1551013425.SGD","LU2471134952.CNY","IE00BJJMRY28.SGD","SG9999014880.SGD","SG9999014898.SGD","LU0471298777.SGD","SG9999015945.SGD","IE0004445015.USD","LU0114720955.EUR","LU0122379950.USD","LU1093756325.SGD","LU1868837136.USD","IE00B4JS1V06.HKD","SG9999014914.USD","LU2211815571.USD","LU2237443895.HKD","LU2456880835.USD","LU1061106388.HKD","LU2360106947.USD","SG9999014906.USD","LU0708995401.HKD","LU1064131342.USD","LU1868837300.USD","LU2265009873.SGD","LU1868836914.USD","LU0820561909.HKD","LU2361045086.USD","LU2552382058.USD","LU0079474960.USD","LU0432979614.USD","LU0823434583.USD","IE00B7KXQ091.USD","LU1232071149.USD","LU2168563687.JPY","LU2491049909.HKD","LU2168564222.USD","LU2602419157.SGD","IE00BJLML261.HKD","LU0256863902.USD","LU2106854487.HKD","LU0094547139.USD","LU2417539215.USD","LU2746668461.USD","IE00BN29S564.USD","IE0004445239.USD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0353189680.USD","LU0820561818.USD","LU0097036916.USD","LU0058720904.USD","LU1804176565.USD","SGXZ51526630.SGD","LU2491050154.USD","LU1988902786.USD","LU1868836757.USD","LU0456855351.SGD","LU2168564495.EUR","LU2264538146.SGD","LU0106261372.USD","LU1720051017.SGD","LU2471134523.USD","LU1720051108.HKD","LU0256863811.USD","LU1093756168.USD","LU2750360997.AUD","LU1974910355.USD","SG9999018865.SGD","IE00B4R5TH58.HKD","IE00BK4W5L77.USD","LU0354030511.USD","IE00BJJMRX11.SGD","IE00BKDWB100.SGD","LU0889565916.HKD","LU0289739699.SGD","LU0385154629.USD","LU0689472784.USD","LU1069344957.HKD","SG9999013999.USD","SG9999001176.SGD","LU0234572021.USD","LU2491050071.SGD","LU2746668974.SGD","LU0109394709.USD","LU2750360641.GBP","SGXZ81514606.USD","LU2087625088.SGD","LU2237438978.USD","IE00BFSS7M15.SGD","LU0823416689.USD","LU0471298694.HKD","LU1057294990.SGD","IE00BFSS8Q28.SGD"],"gpt_icon":0},{"id":"2590651590","title":"诺和诺德股价跌回2021年水平 分析师谨慎看好估值修复","url":"https://stock-news.laohu8.com/highlight/detail?id=2590651590","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590651590?lang=zh_cn&edition=full","pubTime":"2025-12-11 19:27","pubTimestamp":1765452459,"startTime":"0","endTime":"0","summary":null,"market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"566163e37b9d8f8e565f1e9465bbe4ed","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["NVO","LU0154236417.USD","LU1093756325.SGD","IE00BKVL7J92.USD","BK4585","LU1093756168.USD","BK4532","BK4007","BK4588","BK4599","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"1171599262","title":"2025年暴跌50%！诺和诺德遭遇史上最差一年，“减肥药狂潮”仿佛从未发生","url":"https://stock-news.laohu8.com/highlight/detail?id=1171599262","media":"华尔街见闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171599262?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:30","pubTimestamp":1765441808,"startTime":"0","endTime":"0","summary":"今年以来，诺和诺德股价暴跌逾50%，且几乎抹去了自2021年Wegovy获批用于减肥治疗以来的惊人涨幅。礼来后来居上，诺和诺德面临巨大挑战诺和诺德面临的最大威胁来自竞争对手礼来公司的强势表现。礼来股价今年飙升超过28%，与诺和诺德的暴跌形成鲜明对比。Zealand Pharma股价今年也下跌近30%，显示整个欧洲减肥药板块都面临压力。诺和诺德显然没有死。2026年诺和诺德CagriSema药物与礼来Zepbound的直接对比试验结果，以及公司明年的初步业绩指引将成为市场关注焦点。","market":"us","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":{"source":"lsy1762389672944","url":"https://wallstreetcn.com/articles/3761178","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3761178","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"lsy1762389672944","symbols":["NVO","LLY"],"gpt_icon":1},{"id":"2590561218","title":"2026年畅销药预测TOP10","url":"https://stock-news.laohu8.com/highlight/detail?id=2590561218","media":"医药魔方","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590561218?lang=zh_cn&edition=full","pubTime":"2025-12-11 13:14","pubTimestamp":1765430055,"startTime":"0","endTime":"0","summary":"2026年畅销药预测TOP10注：预测数据仅涵盖由指定全球营销合作伙伴预订的销售额，例如赛诺菲负责的度普利尤单抗以及BMS负责的阿哌沙班。与去年对2025年的预测相比，2026年TOP10的产品名单并未发生变化，显示出头部阵营的稳定性。用于2型糖尿病的Mounjaro预计销售额将达258亿美元，跃升至榜单第二位；而用于肥胖症的Zepbound则预计成为第五大畅销药，并成为TOP10中绝对销售额和同比增长率最高的“增长之王”。其2026年预计销售额为197亿美元，排名降至第六位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121113262695370e0f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121113262695370e0f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0965509101.SGD","LU0154236417.USD","LU1699723380.USD","LU2023250504.SGD","SG9999001440.SGD","LU1941712264.USD","LU0058720904.USD","LU0965509283.SGD","IE0009355771.USD","LU1989771016.USD","LU1989772923.USD","SG9999001176.SGD","LU1430594728.SGD","BK4516","LU0320765646.SGD","NVO","BK4532","LU0965508806.USD","LU1057294990.SGD","IE00BFTCPJ56.SGD","LU1941712348.USD","LU0211331839.USD","LU1585245621.USD","LU2125154778.USD","BK4559","LU0289739699.SGD","LU1066051498.USD","LU2361044865.SGD","LU1571399168.USD","SG9999001176.USD","LU0203347892.USD","IE00BBT3K403.USD","SG9999002232.USD","LU1069347547.HKD","LU0965509010.AUD","BK4599","LU1162221912.USD","LU1917777945.USD","IE00BSNM7G36.USD","IE00BLSP4452.SGD","SG9999002224.SGD","IE00B2B36J28.USD","BK4533","LU1035773651.USD","LU1934455863.HKD","LU1934455277.USD","LU1974910355.USD","IE00B1BXHZ80.USD","LU1929549753.HKD","IE00BZ1G4Q59.USD","LU2361045086.USD","LU0070302665.USD","SG9999014575.USD","LU1093756168.USD","SGXZ57979304.SGD","LU1037948897.HKD","IE00BN8TJ469.HKD","LU0234572021.USD","LU2461242641.AUD","LU0265550359.USD","LU0861579265.USD","SG9999013999.USD","IE00BJJMRZ35.SGD","MRK","LU1934455194.USD","LU0985320562.USD","LU2023250843.SGD","LU1037948541.HKD","SG9999014559.SGD","LLY","LU0098860793.USD","LU1116320901.HKD","LU2125154935.USD","SG9999014542.SGD","LU1066053197.SGD","LU1023059063.AUD","LU0320765489.SGD","LU1093756325.SGD","LU0265550946.USD","BK4588","BK4007","IE000M9KFDE8.USD","LU2324357040.USD","LU1291159041.SGD","LU2360032135.SGD","LU0106261372.USD","BK4585","LU1989772840.SGD","IE00BKVL7J92.USD","BK4550","IE00BLSP4239.USD","LU2089984988.USD","LU1066051811.HKD","IE0002141913.USD","LU1066051225.USD","SG9999014567.USD","LU0208291251.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","LU1061106388.HKD","LU0266013472.USD","BK4534","LU1116320737.USD","LU0238689110.USD","LU2361044949.HKD","LU2112291526.USD","LU0122379950.USD","IE00B4R5TH58.HKD","LU0203345920.USD","SG9999015341.SGD","LU2106854487.HKD","LU1983299246.USD","LU0006306889.USD","SG9999015358.SGD"],"gpt_icon":1},{"id":"1169452002","title":"减肥药概念走强，GPCR涨超5%，诺和诺德涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1169452002","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169452002?lang=zh_cn&edition=full","pubTime":"2025-12-10 23:26","pubTimestamp":1765380382,"startTime":"0","endTime":"0","summary":"罗氏控股涨超3%，礼来跟涨。","market":"us","thumbnail":"https://static.tigerbbs.com/5680d8f4d3b53955520e696fc46611e4","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5680d8f4d3b53955520e696fc46611e4"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8c3694a08f44a67f8ee972cef2b11b95","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVO","RHHBY","LLY","GPCR"],"gpt_icon":0},{"id":"2590344084","title":"诺和诺德完成对生物制药公司Akero的收购","url":"https://stock-news.laohu8.com/highlight/detail?id=2590344084","media":"动脉网","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590344084?lang=zh_cn&edition=full","pubTime":"2025-12-09 22:00","pubTimestamp":1765288800,"startTime":"0","endTime":"0","summary":"诺和诺德12月9日宣布已成功完成对生物制药公司Akero Therapeutics的收购。此次收购以每股54美元现金（总价值达47亿美元）及一项不可转让的或有价值权（CVR）作为交易对价，全面收购了Akero所有已发行的普通股及等价物。随着交易的圆满结束，Akero正式成为诺和诺德旗下的全资子公司，其普通股也将随之从纳斯达克全球精选市场退市，不再进行上市交易。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512092209119798b1ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512092209119798b1ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","LU1093756168.USD","BK4588","AKRO","IE00BKVL7J92.USD","LU1093756325.SGD","IE00BZ1G4Q59.USD","BK4532","LU0154236417.USD","BK4585","NVO","BK4007"],"gpt_icon":0},{"id":"2590341068","title":"诺和诺德：已完成对Akero的收购，其普通股将不再在纳斯达克全球精选市场上市或交易。","url":"https://stock-news.laohu8.com/highlight/detail?id=2590341068","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590341068?lang=zh_cn&edition=full","pubTime":"2025-12-09 21:56","pubTimestamp":1765288564,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4532","IE00BKVL7J92.USD","BK4588","IE00BZ1G4Q59.USD","BK4599","AKRO","LU1093756325.SGD","LU1093756168.USD","NVO","LU0154236417.USD","BK4007","BK4585"],"gpt_icon":0},{"id":"2590399358","title":"诺和诺德：乐城引进帕西生长激素注射液，为GHD患儿提供新选择","url":"https://stock-news.laohu8.com/highlight/detail?id=2590399358","media":"财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590399358?lang=zh_cn&edition=full","pubTime":"2025-12-09 11:06","pubTimestamp":1765249561,"startTime":"0","endTime":"0","summary":"帕西生长激素注射液则采用了一项在国际上已有36年应用历史的成熟技术——脂肪酸衍生化制药技术。这项技术已成功应用于地特胰岛素、司美格鲁肽等多个经典药物中，验证了其可靠性与有效性。此外，帕西生长激素分子与人体生长激素分子近似，延长代谢主要依赖于自身体内白蛋白，从7年临床实验随访与真实世界使用观察，药物安全性特征良好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209110822a72c5c50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209110822a72c5c50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU0154236417.USD","LU1093756325.SGD","BK4585","IE00BZ1G4Q59.USD","BK4532","IE00BKVL7J92.USD","NVO","BK4588","BK4599","LU1093756168.USD"],"gpt_icon":1},{"id":"2590395790","title":"年耗数十万！阿尔茨海默病新药入商保，能否破解“记忆困境”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2590395790","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590395790?lang=zh_cn&edition=full","pubTime":"2025-12-09 10:34","pubTimestamp":1765247654,"startTime":"0","endTime":"0","summary":"日前，在2025创新药高质量发展大会上，我国首版《商业健康保险创新药品目录》正式发布。两款近年来最具突破性的阿尔茨海默病对因治疗药物——仑卡奈单抗注射液和多奈单抗注射液双双入选。自今年起，国家医保部门首次探索“商业健康保险”联动医保目录机制，聚焦创新程度高、临床价值大、患者获益显著的药物，旨在通过医保与商业险的协同发力，进一步提高人民群众对重大疾病创新疗法的可负担性和可及性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209103645a43c9924&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209103645a43c9924&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","LU1093756168.USD","NVO","IE00BZ1G4Q59.USD","IE00BKVL7J92.USD","LU1093756325.SGD","BK4132","BK4585","BK4588","LLY","LU0154236417.USD","BK4213","BK4599","BK4007"],"gpt_icon":1},{"id":"2589877119","title":"19种药品纳入首版商保目录，5款CAR-T疗法集体入围，影响有多大？","url":"https://stock-news.laohu8.com/highlight/detail?id=2589877119","media":"澎湃新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589877119?lang=zh_cn&edition=full","pubTime":"2025-12-07 21:37","pubTimestamp":1765114670,"startTime":"0","endTime":"0","summary":"在7日的大会现场，国家医保局相关负责人还为入选商保创新药目录的企业代表颁发了证书。根据此前公布的数据，首版商保创新药目录申报信息共有141份，涉及药品通用名141个，121个通过形式审查，实际参与商保创新药目录价格协商的药品24个。进入商保目录后，公司CAR-T疗法的对外价格还是不变的，但对于保险公司会有一个折扣价格。两款药物均出现在首版目录名单，有望造福更多AD患者。从最终的结果来看，该产品未能进入商保目录。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207213959a439684c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251207213959a439684c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4599","LU1093756325.SGD","BK4585","BK4230","IE00BZ1G4Q59.USD","BK4007","688235","02196","02171","ONC","BK4532","BK4588","LU0154236417.USD","02161","06160","01228","BK4022","NVO","LU1093756168.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2589963378","title":"印度Healthify与诺和诺德达成合作后，计划与更多减肥药企建立合作关系","url":"https://stock-news.laohu8.com/highlight/detail?id=2589963378","media":"环球市场播报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589963378?lang=zh_cn&edition=full","pubTime":"2025-12-05 18:23","pubTimestamp":1764930180,"startTime":"0","endTime":"0","summary":"印度健康科技初创公司 Healthify 的首席执行官表示，在与诺和诺德印度子公司签署合作协议后，该公司正洽谈与更多减肥药企建立合作，以提供健康、营养及生活方式指导服务。　　此次合作是 Healthify 首次与药企达成此类合作，该公司希望通过类似协议扩大其付费用户群体。　　Healthify 主营健康数据追踪业务，同时提供营养与健身建议。　　瓦希什特指出，这项患者支持计划是 Healthify 更广泛减肥计划的一部分，目前该减肥计划已为公司贡献了两位数的营收占比。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-12-05/doc-infztyka7677713.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","BK4585","MNDmain","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4007","NVO","LU1093756168.USD","BK4599","BK4532","IE00BKVL7J92.USD","LU1093756325.SGD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.novonordisk.com","stockEarnings":[{"period":"1week","weight":-0.0261},{"period":"1month","weight":-0.0142},{"period":"3month","weight":-0.2276},{"period":"6month","weight":-0.3524},{"period":"1year","weight":-0.5577},{"period":"ytd","weight":-0.4447}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novo Nordisk A/S成立于1989年，由两家丹麦公司Nordisk Gentofte A/S和Novo Industri A/S合并而成。该公司是一家全球医疗保健公司，也是糖尿病和肥胖症护理领域的全球领导者。该公司拥有广泛的糖尿病和肥胖症护理以及罕见疾病产品组合，包括用于治疗糖尿病和肥胖症的胰高血糖素样肽-1(GLP-1)受体激动剂、现代胰岛素和人胰岛素。","yearOnYearQuotes":[{"month":1,"riseRate":0.522727,"avgChangeRate":0.119015},{"month":2,"riseRate":0.613636,"avgChangeRate":0.028062},{"month":3,"riseRate":0.454545,"avgChangeRate":0.006986},{"month":4,"riseRate":0.613636,"avgChangeRate":0.01505},{"month":5,"riseRate":0.555556,"avgChangeRate":0.018382},{"month":6,"riseRate":0.688889,"avgChangeRate":0.026171},{"month":7,"riseRate":0.488889,"avgChangeRate":-0.001692},{"month":8,"riseRate":0.533333,"avgChangeRate":0.006145},{"month":9,"riseRate":0.555556,"avgChangeRate":-0.002979},{"month":10,"riseRate":0.488889,"avgChangeRate":-0.004606},{"month":11,"riseRate":0.6,"avgChangeRate":0.026574},{"month":12,"riseRate":0.711111,"avgChangeRate":0.047356}],"exchange":"NYSE","name":"诺和诺德","nameEN":"Novo-Nordisk A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺和诺德,NVO,诺和诺德股票,诺和诺德股票老虎,诺和诺德股票老虎国际,诺和诺德行情,诺和诺德股票行情,诺和诺德股价,诺和诺德股市,诺和诺德股票价格,诺和诺德股票交易,诺和诺德股票购买,诺和诺德股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺和诺德(NVO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺和诺德(NVO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}